BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

789 related articles for article (PubMed ID: 28645561)

  • 1. BORIS up-regulates OCT4 via histone methylation to promote cancer stem cell-like properties in human liver cancer cells.
    Liu Q; Chen K; Liu Z; Huang Y; Zhao R; Wei L; Yu X; He J; Liu J; Qi J; Qin Y; Li B
    Cancer Lett; 2017 Sep; 403():165-174. PubMed ID: 28645561
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Positive Feedback Loop of OCT4 and c-JUN Expedites Cancer Stemness in Liver Cancer.
    Kuo KK; Lee KT; Chen KK; Yang YH; Lin YC; Tsai MH; Wuputra K; Lee YL; Ku CC; Miyoshi H; Nakamura Y; Saito S; Wu CC; Chai CY; Eckner R; Steve Lin CL; Wang SS; Wu DC; Lin CS; Yokoyama KK
    Stem Cells; 2016 Nov; 34(11):2613-2624. PubMed ID: 27341307
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SRY and OCT4 Are Required for the Acquisition of Cancer Stem Cell-Like Properties and Are Potential Differentiation Therapy Targets.
    Murakami S; Ninomiya W; Sakamoto E; Shibata T; Akiyama H; Tashiro F
    Stem Cells; 2015 Sep; 33(9):2652-63. PubMed ID: 26013162
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Positive correlation of Oct4 and ABCG2 to chemotherapeutic resistance in CD90(+)CD133(+) liver cancer stem cells.
    Jia Q; Zhang X; Deng T; Gao J
    Cell Reprogram; 2013 Apr; 15(2):143-50. PubMed ID: 23438193
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [BORIS Regulates SOCS3 Expression Through Epigenetic Mechanisms in Human Hepatocellular Carcinoma Cells].
    He JY; Liu QY; Wei L; Liu ZJ; Huang Y; Yu XQ; Li B; Qin Y
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2018 Jan; 49(1):1-7. PubMed ID: 29737080
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Different Effects of BORIS/CTCFL on Stemness Gene Expression, Sphere Formation and Cell Survival in Epithelial Cancer Stem Cells.
    Alberti L; Losi L; Leyvraz S; Benhattar J
    PLoS One; 2015; 10(7):e0132977. PubMed ID: 26185996
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Loss of ATOH8 Increases Stem Cell Features of Hepatocellular Carcinoma Cells.
    Song Y; Pan G; Chen L; Ma S; Zeng T; Man Chan TH; Li L; Lian Q; Chow R; Cai X; Li Y; Li Y; Liu M; Li Y; Zhu Y; Wong N; Yuan YF; Pei D; Guan XY
    Gastroenterology; 2015 Oct; 149(4):1068-81.e5. PubMed ID: 26099525
    [TBL] [Abstract][Full Text] [Related]  

  • 8. miR-589-5p inhibits MAP3K8 and suppresses CD90
    Zhang X; Jiang P; Shuai L; Chen K; Li Z; Zhang Y; Jiang Y; Li X
    J Exp Clin Cancer Res; 2016 Nov; 35(1):176. PubMed ID: 27835990
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Musashi 2 contributes to the stemness and chemoresistance of liver cancer stem cells via LIN28A activation.
    Fang T; Lv H; Wu F; Wang C; Li T; Lv G; Tang L; Guo L; Tang S; Cao D; Wu M; Yang W; Wang H
    Cancer Lett; 2017 Jan; 384():50-59. PubMed ID: 27721018
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Coexpression of gene Oct4 and Nanog initiates stem cell characteristics in hepatocellular carcinoma and promotes epithelial-mesenchymal transition through activation of Stat3/Snail signaling.
    Yin X; Zhang BH; Zheng SS; Gao DM; Qiu SJ; Wu WZ; Ren ZG
    J Hematol Oncol; 2015 Mar; 8():23. PubMed ID: 25879771
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hepatitis B virus PreS1 facilitates hepatocellular carcinoma development by promoting appearance and self-renewal of liver cancer stem cells.
    Liu Z; Dai X; Wang T; Zhang C; Zhang W; Zhang W; Zhang Q; Wu K; Liu F; Liu Y; Wu J
    Cancer Lett; 2017 Aug; 400():149-160. PubMed ID: 28455240
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Knock out CD44 in reprogrammed liver cancer cell C3A increases CSCs stemness and promotes differentiation.
    Han S; Guo J; Liu Y; Zhang Z; He Q; Li P; Zhang M; Sun H; Li R; Li Y; Zeng W; Liu J; Lian L; Gao Y; Shen L
    Oncotarget; 2015 Dec; 6(42):44452-65. PubMed ID: 26540347
    [TBL] [Abstract][Full Text] [Related]  

  • 13. YTHDF2 promotes the liver cancer stem cell phenotype and cancer metastasis by regulating OCT4 expression via m6A RNA methylation.
    Zhang C; Huang S; Zhuang H; Ruan S; Zhou Z; Huang K; Ji F; Ma Z; Hou B; He X
    Oncogene; 2020 Jun; 39(23):4507-4518. PubMed ID: 32366907
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ZHX2 restricts hepatocellular carcinoma by suppressing stem cell-like traits through KDM2A-mediated H3K36 demethylation.
    Lin Q; Wu Z; Yue X; Yu X; Wang Z; Song X; Xu L; He Y; Ge Y; Tan S; Wang T; Song H; Yuan D; Gong Y; Gao L; Liang X; Ma C
    EBioMedicine; 2020 Mar; 53():102676. PubMed ID: 32114388
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lipopolysaccharide supports maintaining the stemness of CD133(+) hepatoma cells through activation of the NF-κB/HIF-1α pathway.
    Lai FB; Liu WT; Jing YY; Yu GF; Han ZP; Yang X; Zeng JX; Zhang HJ; Shi RY; Li XY; Pan XR; Li R; Zhao QD; Wu MC; Zhang P; Liu JF; Wei LX
    Cancer Lett; 2016 Aug; 378(2):131-41. PubMed ID: 27208741
    [TBL] [Abstract][Full Text] [Related]  

  • 16. WM130 preferentially inhibits hepatic cancer stem-like cells by suppressing AKT/GSK3β/β-catenin signaling pathway.
    Ni CX; Qi Y; Zhang J; Liu Y; Xu WH; Xu J; Hu HG; Wu QY; Wang Y; Zhang JP
    Oncotarget; 2016 Nov; 7(48):79544-79556. PubMed ID: 27783993
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Yin Yang 1-mediated epigenetic silencing of tumour-suppressive microRNAs activates nuclear factor-κB in hepatocellular carcinoma.
    Tsang DP; Wu WK; Kang W; Lee YY; Wu F; Yu Z; Xiong L; Chan AW; Tong JH; Yang W; Li MS; Lau SS; Li X; Lee SD; Yang Y; Lai PB; Yu DY; Xu G; Lo KW; Chan MT; Wang H; Lee TL; Yu J; Wong N; Yip KY; To KF; Cheng AS
    J Pathol; 2016 Apr; 238(5):651-64. PubMed ID: 26800240
    [TBL] [Abstract][Full Text] [Related]  

  • 18. IGF2 Is Up-regulated by Epigenetic Mechanisms in Hepatocellular Carcinomas and Is an Actionable Oncogene Product in Experimental Models.
    Martinez-Quetglas I; Pinyol R; Dauch D; Torrecilla S; Tovar V; Moeini A; Alsinet C; Portela A; Rodriguez-Carunchio L; Solé M; Lujambio A; Villanueva A; Thung S; Esteller M; Zender L; Llovet JM
    Gastroenterology; 2016 Dec; 151(6):1192-1205. PubMed ID: 27614046
    [TBL] [Abstract][Full Text] [Related]  

  • 19. IFI44L is a novel tumor suppressor in human hepatocellular carcinoma affecting cancer stemness, metastasis, and drug resistance via regulating met/Src signaling pathway.
    Huang WC; Tung SL; Chen YL; Chen PM; Chu PY
    BMC Cancer; 2018 May; 18(1):609. PubMed ID: 29848298
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Arsenite inhibits the function of CD133
    Tang H; Jin Y; Jin S; Tan Z; Peng Z; Kuang Y
    Tumour Biol; 2016 Oct; 37(10):14103-14115. PubMed ID: 27517564
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 40.